Fears of 'overcaution' by FDA after Vioxx woes go unfounded
Speed of recent votes hints drug approvals not slowing
Drug company officials, Wall Street analysts, and investors have nervously predicted that drug regulators would slow approval of new therapies after safety problems forced Vioxx from the market last year. (Full article: 761 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
